A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis.
Autorzy:
Klughammer B; F. Hoffmann-La Roche AG, Basel, Switzerland. Piali L; F. Hoffmann-La Roche AG, Basel, Switzerland. Nica A; F. Hoffmann-La Roche AG, Basel, Switzerland. Nagel S; F. Hoffmann-La Roche AG, Basel, Switzerland. Bailey L; Roche Products Limited, Welwyn Garden City, UK. Jochum C; Charité - Universitätsmedizin Berlin, Berlin, Germany. Ignatenko S; Charité Research Organisation GmbH, Berlin, Germany. Bläuer A; F. Hoffmann-La Roche AG, Basel, Switzerland. Danilin S; F. Hoffmann-La Roche AG, Basel, Switzerland. Gulati P; F. Hoffmann-La Roche AG, Basel, Switzerland. Hayward J; A4P Bio, Sandwich, UK. Scepanovic P; F. Hoffmann-La Roche AG, Basel, Switzerland. Zhang JD; F. Hoffmann-La Roche AG, Basel, Switzerland. Bhosale S; IQVIA RDS (India) Pvt Ltd, Thane, India. ChongCF; F. Hoffmann-La Roche AG, Basel, Switzerland. Christ A; F. Hoffmann-La Roche AG, Basel, Switzerland.
Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor.
Autorzy:
Tack J; Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium. Vladimirov B; Department of Gastroenterology, University Hospital 'Queen Giovanna- ISUL', Medical University of Sofia, Sofia, Bulgaria. Horny I; Department of Gastroenterology and Internal medicine, Strakonice Hospital, Czech Republic. ChongCF; Currently Hoffmann-La Roche, Formerly Takeda Development Center Asia, Basel, Switzerland. Eisner J; Formerly Takeda Pharmaceuticals International Co., Takeda Pharmaceuticals International Co., Cambridge, USA. Czerniak R; Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA. Takanami Y; Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
Pokaż więcej
Źródło:
Neurogastroenterology and motility [Neurogastroenterol Motil] 2023 Jan; Vol. 35 (1), pp. e14468. Date of Electronic Publication: 2022 Sep 30.
Avirulins, a Novel Class of HIV-1 Reverse Transcriptase Inhibitors Effective in the Female Reproductive Tract Mucosa.
Autorzy:
Cherne MD; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA. michelle_. Hall J; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA. . Kellner A; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA. . ChongCF; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA. . Cole AL; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA. . Cole AM; Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA. .
Pokaż więcej
Źródło:
Viruses [Viruses] 2019 May 01; Vol. 11 (5). Date of Electronic Publication: 2019 May 01.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
